Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOCA vs ALPHADROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.
Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.
Adrenocortical insufficiency (Addison's disease),Salt-losing adrenogenital syndrome
Adjunctive therapy for short-term administration in severe allergic reactions,Management of inflammatory and autoimmune conditions,Off-label: Treatment of certain cancers (e.g., multiple myeloma, lymphoid malignancies)
Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.
0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.
30-35 minutes; clinical context: short duration necessitates frequent dosing or continuous infusion for sustained effect.
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Primarily hepatic metabolism via reduction and conjugation; little is known about specific CYP enzymes.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible (<2%).
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugates (20-25%); biliary/fecal excretion accounts for 5-10%.
~70% bound to plasma proteins (primarily albumin).
Highly protein bound (92-95%), primarily to albumin and alpha-1-acid glycoprotein.
Vd: 0.8-1.2 L/kg; indicates extensive tissue distribution with rapid redistribution from effect sites.
0.8-1.2 L/kg; indicates extensive distribution into total body water with some tissue binding.
Oral: <5% due to extensive first-pass metabolism; IM/SC: 100%.
Oral: 70-80% due to first-pass metabolism; intramuscular: 90-100%.
No specific dose adjustment is recommended for impaired renal function, but monitor for fluid retention and hypertension. Use with caution in patients with significant renal impairment.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of dose; GFR <10 m L/min: avoid use due to risk of accumulation.
No specific dose adjustment for hepatic impairment, but use with caution due to potential electrolyte disturbances.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Dose is not well established; use 0.1 to 0.2 mg/kg intramuscularly daily or adjust based on clinical response and serum electrolytes.
0.01 mg/kg intravenously every 4-6 hours; maximum 0.2 mg/kg/day.
Start at the lower end of the dosing range (e.g., 1 to 2 mg IM daily) and monitor closely for fluid overload, hypertension, and electrolyte imbalances due to age-related decreased renal function and comorbidities.
Initiate with 0.25 mg intravenously every 6 hours; titrate cautiously due to increased sensitivity and renal impairment.
None
None
Fluid overload and edema,Hypokalemia,Hypertension,Cardiac hypertrophy and failure,Increased risk of infection due to immune suppression when used with glucocorticoids
Increased risk of infections due to immunosuppression,Adrenal suppression with prolonged use,Osteoporosis with long-term use,Exacerbation of diabetes mellitus,Psychiatric disturbances
Hypersensitivity to desoxycorticosterone or any component,Severe renal impairment,Hyperkalemia,Hypocalcemia,Congestive heart failure,Systemic fungal infections
Systemic fungal infections,Hypersensitivity to the drug or any component,Administration of live or live attenuated vaccines
No specific food interactions are reported. However, maintain consistent sodium intake; do not restrict salt unless advised. Avoid potassium-rich foods if potassium levels are high. Alcohol may increase the risk of electrolyte disturbances.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Take with food to reduce gastrointestinal irritation. Limit sodium intake to reduce fluid retention; consider potassium-rich foods.
FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: risk of virilization of female fetuses; no adequate human studies; avoid use unless potential benefit outweighs risk.
ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and adrenal suppression. Risk category X.
Excreted in breast milk in low amounts; M/P ratio not established. Potential for adverse effects in nursing infants (e.g., electrolyte disturbances, hypertension). Use caution; consider alternative therapies.
Excreted into breast milk; M/P ratio not reported. Potential for infant adrenal suppression and growth retardation. Breastfeeding not recommended during therapy and for at least 3 months after last dose.
No specific dose adjustments studied; monitor for increased volume of distribution and clearance; adjust based on clinical response and serum electrolyte levels. Use lowest effective dose.
Avoid use in pregnancy; no established dose adjustments; use lowest effective dose if unavoidable; increased clearance may require dose increase, but teratogenicity risk precludes use.
DOCA (desoxycorticosterone acetate) is a mineralocorticoid used in adrenal insufficiency. Monitor serum potassium closely due to risk of hypokalemia from excessive mineralocorticoid activity. DOCA requires intramuscular injection; do not administer intravenously. Use in conjunction with glucocorticoids to mimic cortisol's permissive effects on catecholamines. Avoid in patients with hypertension, heart failure, or renal impairment due to sodium and water retention.
Monitor blood glucose closely in diabetic patients; may cause hyperglycemia. Administer with food to reduce GI upset. Taper dose over 1-2 weeks after prolonged use to avoid adrenal insufficiency. Avoid live vaccines during therapy.
This medication helps maintain salt and water balance in the body.,It is given as an injection into a muscle; do not inject into a vein.,Report signs of excessive fluid retention: swelling in legs, rapid weight gain, shortness of breath.,Monitor for muscle cramps or weakness which may indicate low potassium levels.,Avoid salt substitutes containing potassium without consulting your doctor.,Do not miss appointments for injections as consistent dosing is critical.,Carry medical identification indicating you take corticosteroid replacement therapy.
Take with food or milk to prevent stomach upset.,Do not stop taking this medication suddenly without consulting your doctor.,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising.,Avoid alcohol while on this medication.,Inform all healthcare providers that you are taking Alphadrol.
"Lidocaine, a sodium channel blocker and Class IB antiarrhythmic, inhibits hepatic CYP3A4, the primary enzyme responsible for the metabolism of quazepam, a benzodiazepine sedative-hypnotic. This inhibition reduces quazepam clearance, leading to elevated serum concentrations and enhanced sedative effects. Clinically, this may result in excessive sedation, respiratory depression, psychomotor impairment, and increased risk of falls, especially in elderly patients or those with hepatic impairment."
"Lidocaine and prilocaine are both amide-type local anesthetics that block voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse propagation. When used together, their systemic absorption can lead to additive cardiovascular and central nervous system toxicity, including arrhythmias, seizures, and methemoglobinemia, particularly with high doses or in patients with predisposing conditions."
"Lidocaine, a class Ib antiarrhythmic, inhibits CYP3A4, the primary enzyme responsible for the metabolism of ticagrelor, a P2Y12 platelet inhibitor. This inhibition can lead to increased plasma concentrations of ticagrelor, potentiating its antiplatelet effect and elevating the risk of major bleeding, such as gastrointestinal or intracranial hemorrhage. Conversely, reduced ticagrelor metabolism may also affect conversion to its active metabolite, though net effect still increases overall antiplatelet activity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOCA vs ALPHADROL, answered by our medical review team.
DOCA is a Mineralocorticoid that works by Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.. ALPHADROL is a Mineralocorticoid that works by Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOCA and ALPHADROL depend on the specific clinical indication. These are both Mineralocorticoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOCA is: Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.. The standard adult dose of ALPHADROL is: 0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOCA and ALPHADROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOCA is classified as Category C. FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: ri. ALPHADROL is classified as Category C. ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.